EXACT Sciences Net Worth
EXACT Sciences Net Worth Breakdown | EXAS |
EXACT Sciences Net Worth Analysis
EXACT Sciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including EXACT Sciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of EXACT Sciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform EXACT Sciences' net worth analysis. One common approach is to calculate EXACT Sciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares EXACT Sciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing EXACT Sciences' net worth. This approach calculates the present value of EXACT Sciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of EXACT Sciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate EXACT Sciences' net worth. This involves comparing EXACT Sciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into EXACT Sciences' net worth relative to its peers.
Enterprise Value |
|
To determine if EXACT Sciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding EXACT Sciences' net worth research are outlined below:
| EXACT Sciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.5 B. Net Loss for the year was (204.15 M) with profit before overhead, payroll, taxes, and interest of 1.51 B. | |
| EXACT Sciences has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Acquisition by Kevin Conroy of 102837 shares of EXACT Sciences at 13.96 subject to Rule 16b-3 |
EXACT Sciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in EXACT Sciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to EXACT Sciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
EXACT Sciences Target Price Consensus
EXACT target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. EXACT Sciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 23 | Strong Buy |
Most EXACT analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand EXACT stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of EXACT Sciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEXACT Sciences Target Price Projection
EXACT Sciences' current and average target prices are 62.08 and 106.38, respectively. The current price of EXACT Sciences is the price at which EXACT Sciences is currently trading. On the other hand, EXACT Sciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
EXACT Sciences Market Quote on 29th of November 2024
Target Price
Analyst Consensus On EXACT Sciences Target Price
Know EXACT Sciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as EXACT Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading EXACT Sciences backward and forwards among themselves. EXACT Sciences' institutional investor refers to the entity that pools money to purchase EXACT Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.9 M | Champlain Investment Partners, Llc | 2024-09-30 | 2.5 M | Ameriprise Financial Inc | 2024-06-30 | 2.2 M | Holocene Advisors, Lp | 2024-09-30 | 1.9 M | Macquarie Group Ltd | 2024-06-30 | 1.5 M | Cam Group Holding A/s | 2024-09-30 | 1.5 M | Bellevue Group Ag | 2024-09-30 | 1.4 M | Zevenbergen Capital Investments Llc | 2024-09-30 | 1.4 M | Mackenzie Investments | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 21.6 M | Vanguard Group Inc | 2024-09-30 | 17.8 M |
Follow EXACT Sciences' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.42 B.Market Cap |
|
Project EXACT Sciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.06) | (0.07) |
When accessing EXACT Sciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures EXACT Sciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of EXACT Sciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in EXACT Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of EXACT Sciences. Check EXACT Sciences' Beneish M Score to see the likelihood of EXACT Sciences' management manipulating its earnings.
Evaluate EXACT Sciences' management efficiency
EXACT Sciences has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0676) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.38 in 2024, whereas Fixed Asset Turnover is likely to drop 1.58 in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 17.46 | 18.33 | |
| Tangible Book Value Per Share | (6.17) | (5.87) | |
| Enterprise Value Over EBITDA | 364.80 | 383.04 | |
| Price Book Value Ratio | 4.24 | 4.47 | |
| Enterprise Value Multiple | 364.80 | 383.04 | |
| Price Fair Value | 4.24 | 4.47 | |
| Enterprise Value | 352.5 M | 370.1 M |
Evaluating the management effectiveness of EXACT Sciences allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The EXACT Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 4.886 | Revenue 2.7 B | Quarterly Revenue Growth 0.128 | Revenue Per Share 14.7 | Return On Equity (0.07) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific EXACT Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on EXACT Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases EXACT Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
EXACT Sciences Corporate Filings
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 7th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
EXACT Sciences Earnings Estimation Breakdown
The calculation of EXACT Sciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of EXACT Sciences is estimated to be -0.3327 with the future projection ranging from a low of -0.2675 to a high of -0.0575. Please be aware that this consensus of annual earnings estimates for EXACT Sciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.27 Lowest | Expected EPS | -0.06 Highest |
EXACT Sciences Earnings Projection Consensus
Suppose the current estimates of EXACT Sciences' value are higher than the current market price of the EXACT Sciences stock. In this case, investors may conclude that EXACT Sciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and EXACT Sciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 23 | 60.21% | -0.09 | -0.3327 | -1.16 |
EXACT Sciences Earnings per Share Projection vs Actual
Actual Earning per Share of EXACT Sciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering EXACT Sciences predict the company's earnings will be in the future. The higher the earnings per share of EXACT Sciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.EXACT Sciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as EXACT Sciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of EXACT Sciences should always be considered in relation to other companies to make a more educated investment decision.EXACT Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact EXACT Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2024-07-31 | 2024-06-30 | -0.32 | -0.09 | 0.23 | 71 | ||
2024-05-08 | 2024-03-31 | -0.47 | -0.6 | -0.13 | 27 | ||
2024-02-21 | 2023-12-31 | -0.46 | -0.27 | 0.19 | 41 | ||
2023-11-01 | 2023-09-30 | -0.48 | 0.0043 | 0.4843 | 100 | ||
2023-08-01 | 2023-06-30 | -0.51 | -0.45 | 0.06 | 11 | ||
2023-05-09 | 2023-03-31 | -0.75 | -0.42 | 0.33 | 44 | ||
2023-02-21 | 2022-12-31 | -0.84 | -0.72 | 0.12 | 14 | ||
2022-11-03 | 2022-09-30 | -1.08 | -0.84 | 0.24 | 22 | ||
2022-08-02 | 2022-06-30 | -1.07 | -0.83 | 0.24 | 22 | ||
2022-04-26 | 2022-03-31 | -1.07 | -1.04 | 0.03 | 2 | ||
2022-02-22 | 2021-12-31 | -1.04 | -1.28 | -0.24 | 23 | ||
2021-11-02 | 2021-09-30 | -0.85 | -0.97 | -0.12 | 14 | ||
2021-07-28 | 2021-06-30 | -0.76 | -1.03 | -0.27 | 35 | ||
2021-05-04 | 2021-03-31 | -1.03 | -0.18 | 0.85 | 82 | ||
2021-02-16 | 2020-12-31 | -0.22 | -2.79 | -2.57 | 1168 | ||
2020-10-27 | 2020-09-30 | -0.52 | -0.07 | 0.45 | 86 | ||
2020-07-30 | 2020-06-30 | -0.63 | -0.73 | -0.1 | 15 | ||
2020-05-06 | 2020-03-31 | -0.59 | -0.71 | -0.12 | 20 | ||
2020-02-11 | 2019-12-31 | -0.35 | 0.54 | 0.89 | 254 | ||
2019-10-29 | 2019-09-30 | -0.41 | -0.31 | 0.1 | 24 | ||
2019-07-29 | 2019-06-30 | -0.56 | -0.3 | 0.26 | 46 | ||
2019-04-30 | 2019-03-31 | -0.65 | -0.58 | 0.07 | 10 | ||
2019-02-21 | 2018-12-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2018-10-30 | 2018-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2018-08-01 | 2018-06-30 | -0.32 | -0.3 | 0.02 | 6 | ||
2018-04-26 | 2018-03-31 | -0.37 | -0.33 | 0.04 | 10 | ||
2018-02-22 | 2017-12-31 | -0.24 | -0.18 | 0.06 | 25 | ||
2017-10-30 | 2017-09-30 | -0.3 | -0.23 | 0.07 | 23 | ||
2017-07-25 | 2017-06-30 | -0.35 | -0.27 | 0.08 | 22 | ||
2017-04-27 | 2017-03-31 | -0.41 | -0.32 | 0.09 | 21 | ||
2017-02-21 | 2016-12-31 | -0.39 | -0.34 | 0.05 | 12 | ||
2016-10-26 | 2016-09-30 | -0.42 | -0.36 | 0.06 | 14 | ||
2016-07-26 | 2016-06-30 | -0.55 | -0.46 | 0.09 | 16 | ||
2016-05-03 | 2016-03-31 | -0.52 | -0.49 | 0.03 | 5 | ||
2016-02-24 | 2015-12-31 | -0.47 | -0.41 | 0.06 | 12 | ||
2015-10-29 | 2015-09-30 | -0.44 | -0.45 | -0.01 | 2 | ||
2015-07-20 | 2015-06-30 | -0.44 | -0.44 | 0.0 | 0 | ||
2015-05-04 | 2015-03-31 | -0.41 | -0.4 | 0.01 | 2 | ||
2015-02-24 | 2014-12-31 | -0.39 | -0.38 | 0.01 | 2 | ||
2014-10-27 | 2014-09-30 | -0.31 | -0.39 | -0.08 | 25 | ||
2014-07-22 | 2014-06-30 | -0.25 | -0.24 | 0.01 | 4 | ||
2014-05-01 | 2014-03-31 | -0.19 | -0.23 | -0.04 | 21 | ||
2014-02-20 | 2013-12-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2013-10-29 | 2013-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2013-07-23 | 2013-06-30 | -0.18 | -0.19 | -0.01 | 5 | ||
2013-05-01 | 2013-03-31 | -0.2 | -0.17 | 0.03 | 15 | ||
2013-02-20 | 2012-12-31 | -0.18 | -0.22 | -0.04 | 22 | ||
2012-10-30 | 2012-09-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2012-07-25 | 2012-06-30 | -0.19 | -0.26 | -0.07 | 36 | ||
2012-05-01 | 2012-03-31 | -0.18 | -0.19 | -0.01 | 5 | ||
2012-02-23 | 2011-12-31 | -0.17 | -0.18 | -0.01 | 5 | ||
2011-11-03 | 2011-09-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2011-08-02 | 2011-06-30 | -0.1 | -0.13 | -0.03 | 30 | ||
2011-05-03 | 2011-03-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2011-02-15 | 2010-12-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2010-10-27 | 2010-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2010-07-28 | 2010-06-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2010-05-06 | 2010-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2010-02-16 | 2009-12-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2006-07-24 | 2006-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2006-04-24 | 2006-03-31 | -0.13 | -0.14 | -0.01 | 7 | ||
2006-01-23 | 2005-12-31 | -0.13 | -0.1 | 0.03 | 23 | ||
2005-10-24 | 2005-09-30 | -0.13 | -0.13 | 0.0 | 0 | ||
2005-07-25 | 2005-06-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2005-04-25 | 2005-03-31 | -0.17 | -0.17 | 0.0 | 0 | ||
2005-01-24 | 2004-12-31 | -0.18 | -0.17 | 0.01 | 5 | ||
2004-10-25 | 2004-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2004-07-26 | 2004-06-30 | -0.21 | -0.16 | 0.05 | 23 | ||
2004-04-26 | 2004-03-31 | -0.24 | -0.23 | 0.01 | 4 | ||
2004-01-26 | 2003-12-31 | 0.09 | -0.29 | -0.38 | 422 | ||
2003-10-27 | 2003-09-30 | -0.36 | -0.34 | 0.02 | 5 | ||
2003-07-21 | 2003-06-30 | -0.41 | -0.4 | 0.01 | 2 | ||
2003-04-28 | 2003-03-31 | -0.39 | -0.4 | -0.01 | 2 | ||
2003-01-27 | 2002-12-31 | -0.35 | -0.36 | -0.01 | 2 | ||
2002-10-21 | 2002-09-30 | -0.34 | -0.37 | -0.03 | 8 | ||
2002-07-22 | 2002-06-30 | -0.39 | -0.4 | -0.01 | 2 | ||
2002-04-22 | 2002-03-31 | -0.36 | -0.39 | -0.03 | 8 | ||
2002-01-30 | 2001-12-31 | -0.37 | -0.32 | 0.05 | 13 | ||
2001-10-22 | 2001-09-30 | -0.3 | -0.27 | 0.03 | 10 | ||
2001-07-23 | 2001-06-30 | -0.26 | -0.26 | 0.0 | 0 | ||
2001-04-25 | 2001-03-31 | -0.26 | -0.27 | -0.01 | 3 |
EXACT Sciences Corporate Management
| James Herriott | General VP | Profile | |
| Jeffrey CFA | Chief Officer | Profile | |
| Ana Hooker | Chief Officer | Profile | |
| Aaron Bloomer | Executive Finance | Profile | |
| Vic Parker | Head Sales | Profile | |
| Sarah Condella | Executive Resources | Profile |
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.